Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced NSCLC With EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07655622
What this trial is testing

Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

Who this might be right for
Non-Small-Cell Lung Cancer
Second Affiliated Hospital of Nanchang University 45
Post-approval studies (Phase 4)Study completedNCT02208843
What this trial is testing

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 60
Testing effectiveness (Phase 2)Study completedNCT01565538
What this trial is testing

Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Lung Cancer
Si-Yu Wang 123
Large-scale testing (Phase 3)Not Yet RecruitingNCT06380348
What this trial is testing

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Who this might be right for
Local Advanced or Metastatic NSCLC
Shanghai JMT-Bio Inc. 398
Testing effectiveness (Phase 2)Looking for participantsNCT07538804
What this trial is testing

Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 294
Testing effectiveness (Phase 2)Looking for participantsNCT07637448
What this trial is testing

EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

Who this might be right for
Lung Cancer Non-Small Cell Cancer (NSCLC)EGFR Activating MutationPD-1 Antibody
Nanfang Hospital, Southern Medical University 32
Large-scale testing (Phase 3)Study completedNCT01853826
What this trial is testing

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 481
Testing effectiveness (Phase 2)Looking for participantsNCT06667076
What this trial is testing

Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 480
Testing effectiveness (Phase 2)Active Not RecruitingNCT05920135
What this trial is testing

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

Who this might be right for
EGFR Mutant Advanced Non-Small Cell Lung Cancer
Bridge Biotherapeutics, Inc. 24
Testing effectiveness (Phase 2)Ended earlyNCT04323436
What this trial is testing

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 31
Early research (Phase 1)Active Not RecruitingNCT03993873
What this trial is testing

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorsMET Gene Alterations
Turning Point Therapeutics, Inc. 95
Testing effectiveness (Phase 2)Study completedNCT01542437
What this trial is testing

Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerEGFRHER-2
Instituto Nacional de Cancerologia de Mexico 66
Testing effectiveness (Phase 2)UnknownNCT04895930
What this trial is testing

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
Shanghai Chest Hospital 40
Large-scale testing (Phase 3)Active Not RecruitingNCT05668988
What this trial is testing

DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Who this might be right for
Non-small Cell Lung Cancer
Dizal Pharmaceuticals 324
Not applicableUnknownNCT06174857
What this trial is testing

Efficacy of Osimertinib in Patients With Lung Cancer

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital 100
Testing effectiveness (Phase 2)Ended earlyNCT04512430
What this trial is testing

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Who this might be right for
Non Small Cell Lung CancerEGFR Gene Mutation
Fundación GECP 4
Not applicableStudy completedNCT01955681
What this trial is testing

A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.

Who this might be right for
Locally Advanced or Metastatic EGFR Mutated NSCLC.
AstraZeneca 200
Early research (Phase 1)Looking for participantsNCT06253871
What this trial is testing

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Who this might be right for
HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more
Iambic Therapeutics, Inc 383
Early research (Phase 1)UnknownNCT05555212
What this trial is testing

To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 72
Testing effectiveness (Phase 2)UnknownNCT04592666
What this trial is testing

Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer

Who this might be right for
Lung Cancer, Non-small CellEGFR T790MEGFR Gene Mutation
Fudan University 226
Next Page